Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention

Abstract Aims In the era of personalized medicine, it is of utmost importance to be able to identify subjects at the highest cardiovascular (CV) risk. To date, single biomarkers have failed to markedly improve the estimation of CV risk. Using novel technology, simultaneous assessment of large numbers of biomarkers may hold promise to improve prediction. In the present study, we compared a protein-based risk model with a model using traditional risk factors in predicting CV events in the primary prevention setting of the European Prospective Investigation (EPIC)-Norfolk study, followed by validation in the Progressione della Lesione Intimale Carotidea (PLIC) cohort. Methods and results Using the proximity extension assay, 368 proteins were measured in a nested case–control sample of 822 individuals from the EPIC-Norfolk prospective cohort study and 702 individuals from the PLIC cohort. Using tree-based ensemble and boosting methods, we constructed a protein-based prediction model, an optimized clinical risk model, and a model combining both. In the derivation cohort (EPIC-Norfolk), we defined a panel of 50 proteins, which outperformed the clinical risk model in the prediction of myocardial infarction [area under the curve (AUC) 0.754 vs. 0.730; P < 0.001] during a median follow-up of 20 years. The clinically more relevant prediction of events occurring within 3 years showed an AUC of 0.732 using the clinical risk model and an AUC of 0.803 for the protein model (P < 0.001). The predictive value of the protein panel was confirmed to be superior to the clinical risk model in the validation cohort (AUC 0.705 vs. 0.609; P < 0.001). Conclusion In a primary prevention setting, a proteome-based model outperforms a model comprising clinical risk factors in predicting the risk of CV events. Validation in a large prospective primary prevention cohort is required to address the value for future clinical implementation in CV prevention.

[1]  Stephen A. Williams,et al.  Plasma protein patterns as comprehensive indicators of health , 2019, Nature Medicine.

[2]  T. Vilsbøll,et al.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.

[3]  A. Catapano,et al.  Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. , 2019, Stroke.

[4]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[5]  Jeffrey Dean,et al.  Machine Learning in Medicine , 2019, The New England journal of medicine.

[6]  Declare–Timi Investigators Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[7]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[8]  Charles A. Taylor,et al.  Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease , 2018, EBioMedicine.

[9]  Odyssey Outcomes Investigators Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[10]  A. Konradi,et al.  Epidemiology of cardiovascular risk factors in two population-based studies. , 2018, Atherosclerosis. Supplements.

[11]  Chyke A Doubeni,et al.  Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[12]  Daniel Levy,et al.  Protein Biomarkers of Cardiovascular Disease and Mortality in the Community , 2018, Journal of the American Heart Association.

[13]  Kipp W. Johnson,et al.  Artificial Intelligence in Cardiology. , 2018, Journal of the American College of Cardiology.

[14]  E. Ingelsson,et al.  Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes , 2018, Diabetologia.

[15]  E. Ingelsson,et al.  Circulating proteins as predictors of incident heart failure in the elderly , 2018, European journal of heart failure.

[16]  M. Netea,et al.  Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases , 2017, European heart journal.

[17]  M. Budoff,et al.  Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. , 2017, JACC. Cardiovascular imaging.

[18]  H. Rashid,et al.  Computed Tomographic Coronary Angiography–Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis , 2018, Circulation. Cardiovascular imaging.

[19]  V. Fuster,et al.  Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. , 2017, Journal of the American College of Cardiology.

[20]  J. Leipsic,et al.  Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve , 2017, JAMA cardiology.

[21]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[22]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[23]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[24]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[25]  Mark R Segal,et al.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. , 2016, JAMA.

[26]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[27]  Gediminas Adomavicius,et al.  Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting , 2016, J. Biomed. Informatics.

[28]  Tianqi Chen,et al.  XGBoost: A Scalable Tree Boosting System , 2016, KDD.

[29]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[30]  L. Lind,et al.  Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip , 2015, Stroke.

[31]  K. Borgwardt,et al.  Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.

[32]  Yu-Fang Jin,et al.  Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association , 2015, Circulation.

[33]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[34]  Martin McKee,et al.  Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.

[35]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[36]  M. Bots,et al.  Time-Dependent Changes in Atherosclerotic Plaque Composition in Patients Undergoing Carotid Surgery , 2014, Circulation.

[37]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[38]  S. Butz,et al.  GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice , 2011, Nature Medicine.

[39]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[40]  Miodrag Lovric,et al.  International Encyclopedia of Statistical Science , 2011 .

[41]  Tso-Jung Yen,et al.  Discussion on "Stability Selection" by Meinshausen and Buhlmann , 2010 .

[42]  N. Meinshausen,et al.  Stability selection , 2008, 0809.2932.

[43]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[44]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[45]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[46]  R. Peters,et al.  Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.

[47]  Rich Caruana,et al.  Ensemble selection from libraries of models , 2004, ICML.

[48]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[49]  David H. Wolpert,et al.  Stacked generalization , 1992, Neural Networks.

[50]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.